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Defensins are naturally occurring antimicrobial pep-
tides that disrupt bacterial membranes and prevent
bacterial invasion of the host. Emerging studies
indicate that certain defensins also block virus infec-
tion; however, the mechanism(s) involved are poorly
understood. We demonstrate that human a-defen-
sins inhibit adenovirus infection at low micromolar
concentrations, and this requires direct association
of the defensin with the virus. Moreover, defensins
inhibit virus disassembly at the vertex region, thereby
restricting the release of an internal capsid protein,
pVI, which is required for endosomal membrane
penetration during cell entry. As a consequence, de-
fensins hamper the release of adenovirus particles
from endocytic vesicles, resulting in virion accumula-
tion in early endosomes and lysosomes. Thus, defen-
sins possess remarkably distinct modes of activity
against bacteria and viruses, and their function may
provide insights for the development of new antiviral
strategies.
INTRODUCTION
Antimicrobial peptides are a first line of defense against a wide
range of pathogens. One family of these peptides is defensins,
which are small (18 to 45 residues), cationic, amphiphilic
peptides with broad-range antimicrobial effects. Human defen-
sins are divided into two classes, a- and b-defensins. Human
a-defensins are expressed in neutrophils, Paneth cells, and ep-
ithelial cells of the small intestine, female genitourinary tract,
and airway, while human b-defensins are primarily expressed
in epithelial cells (Ganz, 2003). The mechanism of action of de-
fensins is not known in molecular detail but for bacteria, fungi,
and parasites is thought to involve, at least in part, direct mem-
brane disruption (Brogden, 2005). In contrast, the underlying
modes of defensin activity against distinct viral agents are not
well understood. Defensins have been shown to inhibit infection
by the enveloped viruses HIV-1, vesicular stomatitis virus (VSV),
cytomegalovirus, influenza A virus (IAV), sindbis virus, vaccinia
virus, baculovirus, and herpes simplex virus as well as nonenvel-
oped viruses including human adenovirus (HAdV), adeno-
associated virus (AAV), and human papillomavirus (HPV) (Bas-
tian and Schafer, 2001; Buck et al., 2006; Chang et al., 2005;
Daher et al., 1986; Gropp et al., 1999; Hartshorn et al., 2006;CHarvey et al., 2005; Hazrati et al., 2006; Howell et al., 2007;
Leikina et al., 2005; Virella-Lowell et al., 2000; Wang et al.,
2004); however, the mechanism of action against nonenveloped
viruses in particular is unknown and likely to be distinct from that
against bacteria or enveloped viruses.
HAdV is a nonenveloped virus with a 36 Kb dsDNA genome.
There are 51 recognized serotypes of HAdVs divided into six
species (HAdV-A-F). HAdVs are common pathogens affecting
the respiratory, gastrointestinal, ocular, and excretory systems
and cause generally nonfatal, self-limiting infections in immuno-
competent patients; however, these viruses can cause severe
and frequently fatal disseminated infections in immunocompro-
mised patients, including AIDS and pediatric bonemarrow trans-
plant patients (Kojaoghlanian et al., 2003). Due to their ability to
efficiently infect a broad range of cell types, several HAdV sero-
types are being evaluated in phase I–III clinical trials as vaccine
and gene transfer vectors.
One of the major limitations for the use of HAdV in gene ther-
apy is that systemic administration of these vectors elicits a rapid
and potent innate immune response resulting in diminished
expression of the therapeutic transgene as well as increased
host toxicity. Whereas the adaptive immune response to HAdV
vectors has been studied in detail and strategies exist to limit
its impact on gene transfer, less is known about the innate im-
mune response to these agents. Recent studies have elucidated
the role of the virus genome in eliciting a toll-like receptor 9
(TLR9)-dependent inflammatory response (Iacobelli-Martinez
and Nemerow, 2007; Zhu et al., 2007); however, the role of other
innate effector molecules, including defensins, in the immune
response to HAdV has not been extensively studied.
In this report, we examined the mechanism of inhibition of
a nonenveloped virus infection by human defensins. We have
found that the a-defensins HNP1 and HD5 have potent
antiadenoviral activity. These molecules block HAdV infection
by stabilizing the virus capsid, thereby preventing uncoating
and virus-mediated endosome penetration. These studies reveal
an antiviral mechanism for human defensins that highlights the
broad and diverse activities of the innate immune system.RESULTS
Human a-Defensins Inhibit HAdV-5 Infection
Although human a-defensins HNP1 and HD5 were shown to
inhibit HAdV infection (Bastian and Schafer, 2001; Gropp et al.,
1999; Harvey et al., 2005), their mode of action had not been
elucidated. In initial studies, we determined the inhibitory con-
centrations of HNP1, HD5, and HBD2 against a HAdV-5-basedell Host & Microbe 3, 11–19, January 2008 ª2008 Elsevier Inc. 11
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(eGFP) that uses the Coxsackievirus and adenovirus receptor
(CAR) as its primary attachment receptor. Infection was mea-
sured as the percent of eGFP-positive cells after 18–22 hr com-
pared to control cells infected in the absence of peptide. HNP1
inhibited infection approximately 20-fold at the highest concen-
tration tested with an IC50 between 5 and 6 mM, whereas HD5
was more potent and capable of complete inhibition with an
IC50 between 3 and 4 mM (Figure 1A). In contrast, HBD2, a human
b-defensin, did not inhibit Ad5.F5 at a concentration of 15 mM.No
reduction in cell viability was observed following exposure to the
defensins (data not shown).
Defensins have been previously reported to block virus infec-
tion by preventing attachment to specific host cell receptors
(Lehrer, 2007). We therefore examined whether the a-defensins
were capable of inhibiting HAdV serotypes that use a different
primary receptor, CD46. Both peptides inhibited a HAdV-5-
Figure 1. Human Defensins Inhibit HAdV Infection Irrespective of
Primary Receptor Specificity
Ad5.F5 (A), Ad5.F16 (B), or Ad35.eYFP (C) infection of A549 cells was mea-
sured in the presence of increasing concentrations of HNP1 (filled circle),
HBD2 (filled triangle), or HD5 (open square). Data are given as the mean
percent of eGFP-positive cells compared to control infection in the absence
of defensin from triplicate samples ± SD and are representative of three
experiments.12 Cell Host & Microbe 3, 11–19, January 2008 ª2008 Elsevier Inc.based vector pseudotyped with the HAdV-16 fiber (Ad5.F16) at
virtually the same concentrations and to the same degree as
the CAR-utilizing Ad5.F5 vector (Figure 1B). We also measured
their capacity to inhibit an Ad35.eYFP vector that also uses
CD46 but has a completely heterologous capsid (HAdV-35).
Both peptides inhibited this virus by approximately 30-fold with
an IC50 between 9 and 10 mM. (Figure 1C). These findings sug-
gested that the antimicrobial peptides do not target the primary
receptor interaction. To substantiate this, we performed equilib-
rium cell binding assays with Alexa Fluor 488-labeled Ad5.F5.
These studies demonstrated that HD5 actually increased rather
than blocked virus binding at the IC50 concentration, perhaps by
neutralizing repulsive charge-charge interactions at the mem-
brane, whereas virus binding to cells was inhibited with an ex-
cess of the HAdV5 fiber knob, a competitive inhibitor of HAdV5
binding (see Figure S1 available online). These results confirm
that HD5 does not restrict virus binding to cells and may target
a later step in cell entry.
HD5 Inhibits an Early Step in HAdV Entry
As a first step toward identifying the specific stage of HAdV entry
that is inhibited by these peptides, wemeasured the time depen-
dence of HD5 addition on its ability to inhibit Ad5.F5 infection.
HAdV-2 has been shown biochemically to be internalized within
5 min of binding, to penetrate the endosome after 15 min, and
to reach the nuclear pore complex after 35-45 min (Greber
et al., 1993). We observed that HD5 exhibited a time-dependent
decrease in inhibitory activity (Figure 2). As in the previous exper-
iment, HD5 inhibited infection completely if added at the begin-
ning of the 60 min incubation at 4C (60 min). Approximately
96% inhibition was observed if HD5 was added immediately
prior to warming (0 min). In contrast, 50% inhibition was ob-
served if HD5 was added between 30 and 60 min postwarming.
A similar time dependence of HD5 activity was observed when
serum, which abrogates the ability of HD5 to inhibit Ad5.F5 infec-
tion, was added as a function of time during exposure of A549
cells to HD5 and Ad5.F5 (data not shown). Together, these
experiments indicated that HD5 inhibits an early step in virus en-
try occurring after cell attachment. Moreover, they confirm that
the observed inhibition of transduction by the defensin is due
Figure 2. HD5 Inhibits an Early Step in HAdV Entry
Ad5.F5 infection of A549 cells was measured as a function of the time of addi-
tion of 5.3 mMHD5. Time 0 is the start of incubation at 37C, and negative time
points refer to incubation of virus and HD5 in the absence of cells at 4C. Data
are the mean percent of eGFP-positive cells compared to control infection in
the absence of HD5 for triplicate samples ± SD and are representative of three
experiments.
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eGFP expression.
HD5 Blocks Virus-Mediated Endosome Penetration
Following receptor engagement, association of theHAdV penton
base protein with cellular integrins facilitates virus internalization
(Wickham et al., 1993). To determine if HD5 restricts HAdV up-
take into cells, we measured the accessibility of virus particles
to an anti-hexon antibody as a function of time. In both the pres-
ence and absence of HD5, hexon detection steadily diminished
over time and disappeared with a t1/2 < 3min (Figure S2). This re-
sult demonstrates that HD5 does not block virus internalization.
Upon endocytosis, HAdV undergoes partial disassembly char-
acterized by the loss of the vertex region composed primarily of
the fiber, penton base, and peripentonal hexons. In addition, the
minor capsid protein VI (pVI) is released from the interior of the
partially uncoated capsid and likely plays a central role in endo-
somalysis (Wiethoff et al., 2005). We used a ribotoxin (a-sarcin)
coentry assay to determine the impact of HD5 and HNP1 on vi-
rus-mediated endosomalysis. In this assay, ribotoxin-mediated
inhibition of cellular protein synthesis is indicative of effective vi-
rus-mediated endosome disruption, as the toxin alone is unable
to penetrate the cell. Increasing concentrations of Ad5.F5 in the
presence or absence of 5 mM HD5 or 10 mM HNP1 were mixed
with a-sarcin and incubated with A549 cells. After metabolic
labeling with 35S-Met, cell samples were assayed for 35S-Met
incorporation into cellular proteins (Figure 3). In these experi-
ments, a-sarcin alone had no effect on 35S-Met incorporation.
In the absence of HD5 (WT), the IC90 for
35S-Met incorporation
was 50 ng virus/ml, which corresponds to 4000 particles/cell.
In contrast, the entry-defective ts1mutant HAdV-2 that contains
a mutation in the protease gene and fails to penetrate cell
endosomes (Rancourt et al., 1995) caused only 25% inhibition
at a virus concentration of 100 ng/ml. Strikingly, HD5 or HNP1
prevented HAdV-mediated endosomalysis and was nearly
equivalent to the ts1 control. Neither HNP1 nor HD5 blocked
sarcin-dependent inhibition of cellular protein synthesis in cells
permeabilized with ATP (data not shown). These experiments
suggested that HNP1 and HD5 block HAdV infection by prevent-
ing virus escape from the endosome. To confirm this, we used
Figure 3. HD5 and HNP1 Inhibit HAdV-Mediated Endosomalysis
35S-Met incorporation into cellular proteins was measured as a function of
Ad5.F5 concentration upon infection of A549 cells in the presence of 5 mM
HD5, 10 mM HNP1, or media (WT) and the ribotoxin a-sarcin. The ts1 mutant
of HAdV-2 (ts1) was included as a control. Data are the mean percent of
35S-Met incorporation compared to control uninfected cells for triplicate
samples ± SD and are representative of three experiments.Cconfocal fluorescence microscopy to visualize the subcellular
location of Ad5.F5 labeled with Alexa Fluor 555 in the presence
(HD5+) or absence (HD5) of 10 mM HD5 as a function of time
postinfection (p.i.). Infected cells were costained for the early
endosomal marker EEA1 and for the lysosomal marker Lamp1,
and the volumetric colocalization of virus with each of these
markers was quantified. In the absence of HD5, EEA1 colocaliza-
tion peaked 10 min p.i. at 20% then slowly decreased over time,
consistent with virus escape from these compartments. Lamp1
colocalization also slowly increased to 20% 2 hr p.i., while nu-
clear colocalization steadily increased to a peak of 67% 2 hr
p.i. with a t1/2 of 20–30 min (Figure 4 and Figure S3). In contrast,
in the presence of HD5, virus colocalization with EEA1-labeled
vesicles continued to increase until 20 min p.i. to 42% and only
gradually decreased to 35% by 2 hr p.i. Strikingly, HD5 caused
Ad-Lamp1 colocalization that steadily increased to 57% at 2 hr
p.i. with a t1/2 of 1 hr, indicating a prominent accumulation of
virions in these compartments. Consistent with this, nuclear
colocalization remained close to the initial value (22%) 2 hr p.i.
These results substantiate the biochemical findings that HD5
blocks HAdV-5 infection by preventing virus escape from the en-
dosome, leading to prolonged residency in early endosomes,
subsequent accumulation in lysosomes, and failure to reach
the nuclear membrane.
HD5 Prevents Partial Disassembly of the Virus Particle
The studies described above delineate the step in infection that
is targeted by HD5; however, the precise mechanism involved
remained to be established. HD5 could block HAdV-mediated
endosomalysis either by stabilizing the virus capsid, thereby pre-
venting uncoating, or by disrupting the pH gradient of the endo-
some. Indeed, neutralizing antibodies have been shown to act
through the former mechanism (Wohlfart, 1988; Wohlfart et al.,
1985), while the latter mechanism has been shown for a novel cy-
clic D,L-a-peptide inhibitor of HAdV entry (Horne et al., 2005). To
determine whether antiviral defensins impact HAdV uncoating,
we used a thermostability assay that mimics virus disassembly
in the endosome (Wiethoff et al., 2005). In this assay, tempera-
tures above 43C promote selective removal of the virus vertex
region. Ad5.F5 was incubated with or without 20 mM HD5 at
temperatures from 43C to 73C. Soluble proteins were then
separated from those that remained capsid-associated in a ny-
codenz density gradient. Two gradient fractions comprising the
virus band or the supernatant were probed by immunoblot for
the presence of the fiber or pVI, key components of the HAdV
capsid vertex. Virus incubated with or without HD5 at 43C
was largely intact, with fiber and pVI present primarily in the virus
band (Figures 5A and 5B). However, upon heating wild-type virus
to 49C or above, both fiber and pVI dissociated from the capsid
and were detected in the supernatant. Fiber dissociation in the
ts1 mutant occurred at the same temperature as for wild-type
in the absence of defensin; however, pVI dissociation was only
observed upon heating ts1 above 67C, consistent with previous
studies showing that this mutant virus fails to efficiently release
this membrane lytic protein (Wiethoff et al., 2005). When
Ad5.F5 particles were heated in the presence of HD5, both fiber
(above 61C) and pVI (above 67C) dissociation was observed
at substantially higher temperatures than virions incubated in
the absence of defensin (control). Ad5.F5 incubated with HBD2ell Host & Microbe 3, 11–19, January 2008 ª2008 Elsevier Inc. 13
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that of HD5 samples (data not shown). These studies demon-
strate that certain a-defensins preferentially stabilize the HAdV
capsid.
In further studies, we sought to determine the concentration
dependence of HAdV particle stabilization to relate this to the
IC50 for blocking infectivity. In these experiments, pVI dissocia-
tion was stabilized by 5 mM HD5 or by 10 mM HNP1 (Figure 5C).
These concentrations correlate closely with the concentrations
required to inhibit infection.
One question that arose from these findings is whether
a-defensins are capable of stabilizing diverse HAdV serotypes.
As HNP1 and HD5 inhibit HAdV-35 infection, we examined
whether HD5 altered the thermostability of HAdV-35 (HAdV-B)
and HAdV-12 (HAdV-A) in addition to HAdV-5 (HAdV-C). All three
virus serotypes, representing three species, were stabilized
by HD5 as measured by fiber and pVI release (Figure 6). The
absence or reduction of signal in the supernatant of samples
treated at 50C without HD5 is due to poor reactivity of the anti-
gens with antibodies raised against HAdV-5 and loss of capsid-
dissociated protein, likely due to adsorption in the sample tube.
Taken together, these experiments indicate that the a-defensins
HNP1 and HD5 stabilize multiple HAdV serotypes by blocking
dissociation of the capsid vertex region in the endosome and
preventing pVI-mediated endosomalysis.
HD5 Binds Directly to Virus Particles
The preceding studies indicated that a-defensins stabilize the
HAdV capsid, suggesting that the peptides bind directly to the
virus. To examine this possibility, HD5was incubated in the pres-
ence and absence of Ad5.F5 under physiological salt conditions
(150 mM) and centrifuged over a nycodenz gradient. Gradient
fractions were then probed by immunoblot for HD5 (Figure 7B).
In the absence of Ad5.F5, HD5 remained in the supernatant
(fractions 1 and 2), whereas, in the presence of virus, HD5 wasFigure 4. Ad5.F5Accumulates inLysosomes
in the Presence of HD5
The colocalization of Alexa Fluor 555-labeled
Ad5.F5 with EEA1, a marker for early endosomes
(A), Lamp1, a marker for lysosomes (B), and DAPI,
anuclearmarker (C), in thepresence (opensymbols)
or absence (closed symbols) of 10 mM HD5. Data
are the mean volumetric colocalization ± SEM for
an average of 51 cells per data point. (D) Represen-
tative cells at 2 hr p.i. with Alexa Fluor 555-conju-
gated virus (red) stained for Lamp1 (green) and
DAPI (blue). Panels are Z-profiles of sequential
Z-series. Scale bar is 10 mm. Percentages are the
volumetric colocalization values for virus/DAPI or
virus/Lamp1 for each cell.
localized to the virus band (fraction 5).
These results confirm a direct association
between HD5 and HAdV. Previous stud-
ies have shown that the antimicrobial
activity of HD5 is salt sensitive, suggest-
ing that defensin association with its tar-
get substrate involves electrostatic inter-14 Cell Host & Microbe 3, 11–19, January 2008 ª2008 Elsevier Inc.to further substantiate that binding to virus is required for the
HD5 inhibitory activity, we examined the effect of increasing
NaCl concentration on HD5 binding to the virus as well as its im-
pact on virus infection. The ability of HD5 both to inhibit infection
(Figure 7A) and to bind to virus (Figure 7B) are abrogated at
superphysiologic salt concentrations (>150 mM). In contrast,
normal defensin activity and virus binding was maintained at
physiologic (150 mM) NaCl. Therefore, the antiviral activity of
HD5 depends upon its direct interaction with the virus capsid.
DISCUSSION
Antimicrobial peptides are potent innate immune effectors that
have been conserved through evolution (Lehrer, 2007). Defen-
sins were first identified and have been most extensively studied
as antibacterial agents. Accumulating evidence has shown that
defensins and other families of antimicrobial peptides interact
directly with and disrupt microbial and model membranes, the
effects of which are not limited to gross membrane deformation
or lysis and include such mechanisms as dissipation of ionic and
pH gradients (Brogden, 2005). There is also evidence for defen-
sins and other antimicrobial peptides targeting DNA, RNA, and
protein synthesis as well as other intracellular metabolic pro-
cesses (Brogden, 2005). Although best known for their antibac-
terial activity, emerging studies are beginning to address the
antiviral properties of these peptides.
A major gap in our understanding of defensin-mediated neu-
tralization of viruses is their mode of action. In this report, we
have identified the mechanism by which two human a-defensins
restrict infection by a nonenveloped virus. We found that, for
HAdV infection, inhibition occurs early during entry, and detailed
studies identified endosome penetration as the specific step that
was blocked. Consistent with this observation, both peptides
bound to and stabilized the virus capsid, preventing partial un-
coating at concentrations that correlate closely with the IC50
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Protein VI is an internal capsid component that contains an N-
terminal amphipathic a-helix. Although the precise location of
this protein in the capsid is still being refined (Saban et al.,
2006), it is released along with the vertex proteins, penton
base and fiber, by partial uncoating of the virus capsid (Wiethoff
et al., 2005). Virus-dependent membrane disruption correlates
with uncoating, and we recently identified pVI as the major lytic
factor (Wiethoff et al., 2005). Our current studies provide support
for the model that partial virus uncoating is required for mem-
brane disruption and provide a molecular mechanism for the
inability of virus to penetrate the endosome in the presence of
defensins.
Our study represents a careful quantification of the antiviral
activity of a-defensins against HAdV, although this activity was
identified previously (Bastian and Schafer, 2001; Gropp et al.,
1999; Harvey et al., 2005). Both HNP1 and HD5 inhibit HAdV in-
fection at low micromolar concentrations, comparable to prior
studies (Bastian and Schafer, 2001). Also consistent with these
Figure 5. HD5 Stabilizes the Virus Capsid for Fiber and pVI Disso-
ciation
Gradient fractions from the supernatant (sup) and virus band (band) of Ad5.F5
samples incubated with (HD5+) or without (HD5) 20 mMHD5 at the indicated
temperatures were probed for fiber (A) or pVI (B) by immunoblot. The ts1 mu-
tant was included as a control. (C) Gradient fractions from the supernatant
(sup) and virus band (band) of Ad5.F5 samples incubated at 49C with the in-
dicated concentrations of HD5 (top) or HNP1 (bottom) were probed for pVI by
immunoblot. Data are representative of three experiments.Cstudies, we observed that HBD2, a b-defensin, had no antiviral
activity (Bastian and Schafer, 2001; Harvey et al., 2005). No
purified b-defensin with anti-HAdV activity has been reported;
however, in limited studies we found that the b-defensin HBD3
was also capable of inhibiting Ad5.F5 with an IC50 between 5
and 10 mM (data not shown). Also in accord with past studies,
we observed that FBS inactivates the antiviral activity of HNP1
and HD5 (data not shown) (Chang et al., 2005; Daher et al.,
1986), although the antiviral activity of HNP1 and HD5 against
HPV was not affected by 10% serum (Buck et al., 2006). Studies
of the antibacterial activities of some a-defensins have shown
that physiologic salt concentrations inactivate their activity (Por-
ter et al., 1997b); however, as in our experiments, the antiviral
effects of HNP1 against HSV-1 were observed at physiologic
salt concentrations (Daher et al., 1986). The IC50 values of
HNP1 and HD5 against HAdV-5 in our studies are also similar
to the antiviral activity of these peptides against other viruses
(Buck et al., 2006; Chang et al., 2005; Daher et al., 1986; Hazrati
et al., 2006).
Our present findings reveal a previously unidentified mecha-
nism of antiviral action for defensins. Direct membrane-disrupt-
ing activity may contribute to the inhibition of enveloped viruses.
A number of studies have also shown that defensins block
protein-protein interactions required for infection. For HIV-1,
HNP1–3, as lectins, have been shown to bind to gp120 and
CD4, and this binding may contribute to inhibition of infection
(Wang et al., 2004), although other mechanisms also contribute
to a-defensin-mediated inhibition of HIV-1 (Chang et al., 2005).
In addition, the q-defensin-like cyclic peptide retrocyclin, which
is also a lectin (Wang et al., 2004), has been shown to bind to
gp41 and block formation of the post-fusion, helical bundle con-
formation of gp41 that has been linked to membrane fusion
(Gallo et al., 2006). Retrocyclin has also been shown to restrict
IAV fusion by crosslinking cellular membrane glycoproteins,
a general mode of inhibition by this peptide that is also effective
against VSV and baculovirus infection (Leikina et al., 2005). For
HSV-2, several a- and b-defensins have been shown to block
infection (Hazrati et al., 2006). A number of these peptides block
virus attachment to cells and bind to either the viral gB glycopro-
tein or to cellular heparin sulfate receptors; however, several also
block postentry steps by an unknown mechanism (Hazrati et al.,
Figure 6. HD5 Stabilizes the Capsids of Multiple HAdV Serotypes
Gradient fractions from the supernatant (sup) and virus band (band) of Ad5.F5
(Ad5), HAdV-12 (Ad12), and Ad35.eYFP (Ad35) samples incubated at the indi-
cated temperatures with or without 20 mM HD5 were probed for fiber (left
panel) or pVI (right panel) by immunoblot. Data are representative of three ex-
periments.ell Host & Microbe 3, 11–19, January 2008 ª2008 Elsevier Inc. 15
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sins; nonetheless, these peptides have been shown to inhibit
infection by HPV (Buck et al., 2006), AAV (Virella-Lowell et al.,
2000), and HAdV (Bastian and Schafer, 2001; Gropp et al.,
1999; Harvey et al., 2005). For HPV, time course experiments
suggested that an early step in infection was inhibited, and
microscopic examination of cells infected in the presence of in-
hibitory concentrations of defensins showed that virus appeared
to be trapped in endosomes (Buck et al., 2006). Although themo-
lecular basis for HPV inhibition was not explored, these results
are strikingly similar to our findings for HAdV and may indicate
that defensins use a common mode of neutralization for nonen-
veloped viruses.
In keeping with the broad-spectrum antiviral activity of defen-
sins, we were able to demonstrate inhibition of multiple HAdV
serotypes representing three HAdV species. Our biochemical
studies of viruses from HAdV-A, -B, and-C suggest that the
peptides inhibit these viruses via the same mechanism. One
previous report described HNP1 activity against the respiratory
tropic HAdV-B serotype 3, but not against the ocular tropic
HAdV-D serotypes 8 and 19 (Harvey et al., 2005). We also ob-
served differences in the IC50 values of HNP1 and HD5 against
Ad5.F5 and Ad35.eYFP. These differences likely reflect sero-
type-specific alterations in the binding site(s) of the defensins
for the capsid. Our studies have not been able to fully charac-
terize the capsid component to which the a-defensins bind in
order to achieve neutralization. HAdV has a large and complex
capsid architecture that has yet to be revealed at high resolu-
tion (Saban et al., 2006). Hexons from both HAdV-5 and
HAdV-35 have strong net negative charges (calculated to be
23.8 and 22 at pH 7, respectively) making hexon a likely
target for electrostatic interactions with the positively charged
defensins, consistent with the ability of increasing salt concen-
trations to abrogate HD5 binding to the virus (Figure 7). Hexons
from HAdV-8 and HAdV-19 are less negatively charged (12.9
and 18.7, respectively), although it is unclear if these differ-
ences are significant. Preliminary studies suggest that HD5
binds to hexon and competes with anti-hexon antibody binding
to capsid (see Figure S2 and data not shown); however, the16 Cell Host & Microbe 3, 11–19, January 2008 ª2008 Elsevier Inc.specificity of this interaction and the potential to bind to other
capsid proteins remain to be addressed. The finding that fiber
dissociation is also stabilized suggests that the defensins bind
to more than just hexon, as hexon does not directly associate
with fiber. In this respect, defensin-mediated capsid stabiliza-
tion differs from that inherent in the ts1 mutant HAdV-2. This vi-
rus is also blocked at endosome escape (Greber et al., 1996),
and our current studies as well as previous observations from
our laboratory have shown that the capsid of this mutant virus
is more thermostable (Wiethoff et al., 2005). This stability has
been attributed to the presence of preproteins in the capsid
(Hannan et al., 1983); however, in the ts1 mutant, fiber associ-
ation with the capsid is as labile as in wild-type virus. Structural
studies of HAdV in complex with a-defensin are needed to de-
lineate the precise mechanism by which these peptides bind to
and stabilize the virus capsid. Comparison of this structure with
that of the ts1 mutant capsid and of the wild-type capsid may
provide insight into the process of stepwise disassembly of the
capsid during infection.
One question arising from our present findings is the clinical
relevance of these antimicrobial peptides in controlling viral
pathogenesis. HAdVs have broad tissue tropism, with specific
serotypes preferentially infecting the respiratory, urinary, gastro-
intestinal, and ocular tissues (Kojaoghlanian et al., 2003). HNP1
is primarily expressed in neutrophils, where it is highly concen-
trated in azurophil granules (Ganz et al., 1985) and is also
expressed by NK and T cells (Agerberth et al., 2000). HNP1–3
are detectable in normal tears, lacrimal gland tissue, and in-
flamed conjuctiva (Haynes et al., 1999). They are also detectable
in the lung, and their levels are increased in some lung diseases
(Bals and Hiemstra, 2004). HD5 is primarily secreted by Paneth
cells of the intestine (Porter et al., 1997a), but also by nasal
and bronchial epithelial cells (Frye et al., 2000). HNP1–3 are
constitutively expressed in neutrophils, where they achieve
high local concentrations through the fusion of granules with
phagosomes (Ganz, 2003; Selsted and Ouellette, 2005), but
they can also reach antimicrobial concentrations in extracel-
lular compartments (Panyutich et al., 1993). Secretion of HD5
can be stimulated by infectious agents, through TLR- andFigure 7. HD5 Binding to HAdV Correlates with Inhibition of Infection
(A) Ad5.F5 infection of A549 cells wasmeasured in the presence and absence of 10 mMHD5 and increasing concentrations of NaCl. Data are the mean percent of
eGFP-positive cells from three independent experiments ± SD.
(B) Nycodenz gradient fractions from samples of Ad5.F5 incubated with or without 20 mM HD5 at the indicated concentrations of NaCl were probed for HD5 by
immunoblot. Fraction 1 is derived from the top of the gradient, and the virus banded in fraction 5. Data are representative of three experiments.
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et al., 2004). In addition to being directly antiviral, some defensin
expression levels are elevated by virus infection (Aceti et al.,
2006; Proud et al., 2004), although the elicited defensins are
not always directly antiviral (Proud et al., 2004). This response
may be part of a general inflammatory response to virus, as
defensins have also been shown to have chemokine and cyto-
kine activity (Selsted and Ouellette, 2005). Experiments to
address the capacity of HAdV infection to elicit increased defen-
sin expression in cultured conjuctival tissue suggested that
HAdV infection marginally decreased the expression of HBD-1
(Harvey et al., 2005); however, the a-defensins studied here
were not expressed by these tissues. The capacity of HAdV to
induce defensin expression or secretion in other tissues or
from other cell types and the consequences of heightened ex-
pression or secretion of a- and b-defensins in inflamed tissues
on gene transfer by HAdV vectors remain to be studied.
The mechanism of virus neutralization described here reveals
both the redundancy and diversity of the immune response to vi-
rus. Virus neutralization through stabilization of the HAdV capsid
has been postulated as a mechanism for antibody-mediated
neutralization (Wohlfart, 1988). Virus exposed to certain neutral-
izing anti-hexon antisera is localized to cytoplasmic vacuoles,
consistent with a failure to escape the endosome (Wohlfart
et al., 1985). Although known to be used by the adaptive immune
system, a role for this type of mechanism in innate immunity has
not been previously described. Defensin binding may also
impact or synergize with other aspects of the innate immune
response to HAdV. Defensins have been shown to stimulate an
inflammatory response at least in part through mast cell chemo-
taxis and degranulation (Befus et al., 1999; Niyonsaba et al.,
2002; Selsted and Ouellette, 2005), and a multivalent complex
of virus and defensin may augment this response. Also, recent
reports have shown that the HAdV genome stimulates a type I in-
terferon response through TLR9-dependent and -independent
signaling (Iacobelli-Martinez and Nemerow, 2007; Zhu et al.,
2007). It is unknown how capsid stabilization by a-defensins
would impact this response. Recent work from our laboratory
suggests that HAdVs using CD46 versus CAR as a primary re-
ceptor elicit a more potent interferon response in human PBMCs
(Iacobelli-Martinez and Nemerow, 2007). CD46-utilizing HAdVs
have been shown to have altered trafficking in the cell and may
reside longer in the endosomal pathway than CAR-utilizing vi-
ruses, which are thought to penetrate the early endosome (Miya-
zawa et al., 2001). It is possible that defensin-stabilized virusmay
reach the late endosome at higher frequency, stimulating a more
potent interferon response. Alternatively, defensin binding may
attenuate the TLR9-dependent interferon response by prevent-
ing virus uncoating and genome exposure.
In summary, our studies have revealed a mechanism of inhibi-
tion of nonenveloped viruses by human antimicrobial peptides.
Comparison with other studies, particularly those of HPV, sug-
gests that this may be a general mechanism for inhibition of
nonenveloped virus infections. Furthermore, it is tempting to
speculate that other classes of antimicrobial peptides may abro-
gate infection by a similar mechanism. Therefore, these studies
provide insight into the broad-spectrum antiviral activity of these
innate immune effectors and could point theway for the develop-
ment of antiviral agents that target virus disassembly.CEXPERIMENTAL PROCEDURES
Cell Lines and Reagents
Tissue culture reagents were obtained from Invitrogen (Carlsbad, CA). Human
A549 and 293 cells were fromATCCandpropagated in DMEMmedium supple-
mented with 10% fetal bovine serum (Omega Scientific, Tarzana, CA), 10 mM
HEPES (pH 7.55), 4 mM L-glutamine, 100 units/ml penicillin, 100 mg/ml strep-
tomycin, and 0.1 mM nonessential amino acids (complete DMEM).
Synthetic HNP1, HBD2, andHD5were obtained fromPeptides International,
Inc. (Louisville, KY) at >99% purity and were reconstituted in sterile water to
100 mM following the manufacturer’s instructions and stored at 80C. In all
experiments using these stock solutions, isotonicity wasmaintained by the ad-
dition of NaCl to the sample.
Antibodies
The 9C12 anti-HAdV-5 hexon mAb (Varghese et al., 2004) was obtained from
Robert Ralston (Schering-Plough, Kenilworth, NJ) and used at 1 mg/ml. The
anti-fiber mAb 4D2 was obtained from NeoMarkers (Lab Vision Corporation,
Fremont, CA) and used at 1 mg/ml. An affinity purified polyclonal rabbit anti-
body against pVI was a kind gift of Harold Wodrich (Institute of Molecular Ge-
netics of Montpellier, Montpellier, France). A polyclonal rabbit antiserum
against HD5 was a kind gift of Edith Porter (California State University Los An-
geles, Los Angeles, CA). The anti-Lamp1 and anti-EEA1 mAbs were from BD
PharMingen (San Jose, CA).
Adenovirus Production and Fluorescent Labeling
The replication-defective HAdV vectors used in these studies were HAdV-5-
based, E1/E3-deleted vectors containing a CMV promoter-driven enhanced
green fluorescent protein (eGFP) reporter gene cassette and expressing either
the endogenous HAdV-5 fiber (Ad5.F5) or the HAdV-16 fiber (Ad5.F16) in the
virus backbone (Nepomuceno et al., 2007). HAdV-12 (Ad12) was obtained
from ATCC. A replication-competent HAdV-35-based vector containing
a CMV promoter-driven enhanced yellow fluorescent protein (eYFP) reporter
gene cassette in place of E3 (Ad35.eYFP) was obtained from Andrea Gam-
botto (University of Pittsburgh, Pittsburgh, PA). The temperature-sensitive mu-
tant of HAdV-2, HAdV-2ts1 (ts1), was obtained from Joseph Weber (University
of Sherbrooke, Quebec, Canada).
HAdVs were propagated in 293 cells and purified by CsCl density gradient
as previously described (Wu et al., 2004). The ts1 mutant was propagated at
the nonpermissive temperature of 39.5C as previously described (Wiethoff
et al., 2005). Viral protein concentration was determined by the Bio-Rad Pro-
tein Assay (Bio-Rad, Richmond, CA) with a bovine serum albumin standard
and used to calculate the viral particle concentration (1 mg = 4 3 109 virions).
Alternatively, the viral particle concentration was determined by UV absor-
bance of heat- and SDS-disrupted particles (1 A260 = 1 3 10
12 virions).
To fluorescently label virus particles, purified virus was dialyzed against PBS
for 2 hr at 4C. Virus concentrationwas adjusted to 1.1mg/mlwith PBS, and1M
sodium bicarbonate (pH 8.3) was added to a final concentration of 100 mM.
Alexa Fluor 488 carboxylic acid, tetrafluorophenyl ester (Invitrogen) or Alexa
Fluor 555 carboxylic acid, succinimidyl ester (Invitrogen) was dissolved in
100 ml 0.1 M sodium bicarbonate (pH 8.3), and 5–15 ml of the dye solution
was added to 100 ml aliquots of virus. Samples were incubated at room
temperature (RT) in the dark for 1 hr. Free dye was removed by dialysis at
4C against three changes of 40 mM Tris, 150 mM NaCl, 2 mM MgCl2,
10% glycerol (pH 8.1) or by gel filtration using P-30 spin columns (Bio-Rad)
pre-equilibrated with the same buffer. Aliquots of labeled virus were snap fro-
zen in LN2 and stored at 80C. Dye incorporation was determined by UV
spectroscopy. Typical dye/capsomer ratios were between 0.5 and 2. The titer
of labeled virus on infection of A549 cells was compared to that of mock-
labeled virus (incubated without dye), and only labeled virus with a titer within
95% of control was used for subsequent experiments.
Inhibition of Infection and Flow Cytometry Analysis
To determine the concentration of defensin required to inhibit infection, in-
creasing concentrations of peptide were added to virus in DMEM without
serum (SFM) and incubated on ice for 45 min. The mixture was then added
to 5 3 104 A549 cells in 96-well tissue culture plates that had been washed
twice with SFM to remove FBS. After incubation for 2 hr at 37C, unbound virusell Host & Microbe 3, 11–19, January 2008 ª2008 Elsevier Inc. 17
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16–20 hr. Cells were trypsinized, washed, and resuspended in PBS/0.2%
sodium azide/1% FBS; and 10,000 cells were acquired on a FACScan, FAC-
Sort, FACSCalibur, or BD LSR II flow cytometer and analyzed for eGFP or
eYFP expression using CellQuest software (BD Biosciences) or FlowJo soft-
ware (Tree Star, Inc.). Only viable cells, based on forward and side scatter pa-
rameters, were used in the analyses. Data are expressed as a percent of
control infection in the absence of peptide ± SD. Typically, a virus MOI (by
particles) of 1500 (Ad5.F5), 200 (Ad5.F16), or 1000 (Ad35.eYFP) yielded
70%–90% positive cells in the control samples.
To determine the time course of HD5-mediated inhibition, parallel samples
of Ad5.F5 were incubated with or without 5 mMHD5 in SFM at 4C for 1 hr. Vi-
rus was then added to A549 cells (washed twice with SFM) and incubated at
37C. HD5 was added at the indicated time points before or during this incu-
bation. After a total of 2 hr at 37C, complete DMEMwas added, and cells were
incubated for an additional 16–20 hr before being analyzed for eGFP expres-
sion by flow cytometry as above.
To determine the effect of increasing NaCl concentrations on HD5-mediated
inhibition, parallel samples of Ad5.F5 were incubated with or without 10 mM
HD5 in SFM containing various concentrations of NaCl on ice for 45 min. Sam-
ples were then added to A549 cells (washed twice with cold SFM) and incu-
bated at 4C. After 30 min, samples were shifted to 37C, incubated for
45 min, washed twice, and incubated for an additional 16–20 hr before being
analyzed for eGFP expression by flow cytometry as above.
Adenovirus-Mediated Endosomalysis
A549 cells were plated at 50,000 cells/well in 96-well tissue culture dishes
with black walls and clear bottom (Costar) 16 hr prior to infection. One hour
prior to infection, cells were washed with PBS and incubated at 37C with
DMEM without cysteine, methionine, or FBS (DMEM). In parallel, Ad5.F5 or
ts1 (100 ng/ml) was incubated with or without 10 mM HNP1 or 5 mM HD5
and 0.1 mg/ml a-sarcin (EMD Chemicals, Inc., San Diego, CA) in DMEM
for 1 hr on ice. The virus/defensin/sarcin mixtures were serially diluted intome-
dia containing the same concentrations of a-sarcin and defensin such that only
the virus concentrations were altered. Themedia were removed from the cells,
the serially diluted viruses were added (50 ml/well) to triplicate wells, and the
cells were incubated at 37C. After 2 hr, the media were removed and cells
were washed with PBS. DMEM (50 ml/well) containing 10% dialyzed FBS
and 0.1 mCi/well [35]S-methionine (GE Healthcare) was added, and samples
were incubated at 37C. After 2 hr, cells were washed twice with PBS and
placed on ice. Ice-cold 5% TCA (50 ml/well) was added, and samples were in-
cubated on ice. After 1 hr, samples were washed twice with ice-cold 100%
ethanol and air-dried overnight. Samples were solubilized with 1% SDS and
0.1N NaOH (10 ml/well) by shaking for 10 min. The solution was neutralized
by adding 2 ml/well 0.6 N HCl. Microscint-20 (Packard) scintillation cocktail
was added, and samples were read using a Topcount (Packard) scintillation
counter.
Fluorescence Microscopy
Alexa Fluor 555-labeled Ad5.F5 (6.3 3 108 particles/sample) was incubated
with or without 10 mMHD5 in SFM for 45 min on ice. A549 cells plated on glass
coverslips were washed twicewith cold SFMand placed on ice. Virus/defensin
was added (45 ml/coverslip), and samples were incubated at 4C. After 45 min,
samples were shifted to 37C. After the indicated incubation times, cells were
washed twice with PBS, fixed in 4% paraformaldehyde in PBS for 15 min
at RT, washed once with PBS, permeabilized and quenched with 0.5% Triton
X-100/20 mM glycine in PBS for 15 min at RT, and blocked in 2% BSA in Tris-
buffered saline (TBS). Cells were stained with primary antibodies for 45 min at
RT, washed with TBS, stained with an Alexa Fluor 488-conjugated goat anti-
mouse IgG secondary antibody (Invitrogen), washed with TBS, stained with
1 mM DAPI (Sigma) in water for 10 min at RT, washed, and mounted with Pro-
long Gold antifade (Invitrogen). Z-series images were acquired with a Rainbow
Radiance 2100 laser scanning confocal microscope attached to a Nikon
TE2000-U inverted microscope (Zeiss, Peabody, MA) using a 603 oil immer-
sion objective (PlanApo, 1.4 na) and LaserSharp 2000 software (Zeiss). Laser
lines and filter sets were lex 405 nm, lem 450SP/420LP nm (DAPI); lex 488 nm,
lem 530SP/500LP nm (Alexa Fluor 488); and lex 543 nm, lem 610SP/570LP nm
(Alexa Fluor 555). Z-series were analyzed by first determining the threshold for18 Cell Host & Microbe 3, 11–19, January 2008 ª2008 Elsevier Inc.signal over background and then for volumetric colocalization above this
threshold using Imaris software version 5.0.3 (Bitplane, Saint Paul, MN).
Z-profiles of images showing signal above threshold were created in ImageJ.
Figure layouts from these images were created in Photoshop.
Adenovirus Thermostability Assay
Ad5.F5, Ad12, Ad35.eYFP, or ts1 (1.7 mg) was incubated with or without the
indicated concentrations of HNP1 or HD5 for 45 min in SFM plus 0.05%
BSA on ice. Parallel samples (45 ml) were incubated for 10 min at the indicated
temperatures, cooled to RT, and loaded onto discontinuous gradients consist-
ing of 300 ml of 30% nycodenz and 200 ml of 80% nycodenz in 50 mM NaCl,
20 mM HEPES (pH 7.4). Gradients were centrifuged at 209,000 3 g (ave) for
2 hr at 4C using an SW55ti rotor with adaptors (Beckman) in ultraclear centri-
fuge tubes. Fractions were taken from the gradient supernatant (sup) and the
gradient interface containing a visible band of virus (band). Samples were
reduced with DTT, boiled, separated by SDS-PAGE, transferred to nitrocellu-
lose, and probed by immunoblot for pVI and fiber.
HD5 Binding to Adenovirus Assay
Ad5.F5 (1.7 mg) was incubated with or without 20 mM HD5 for 45 min in SFM
with increasing concentrations of NaCl on ice. Samples were loaded onto ny-
codenz gradients and centrifuged as above. Five 75 ml fractions were taken
from the top of the gradient (the visible virus band was collected in fraction
5) and transferred to an Immobilon-Psq PVDF membrane (Millipore) using
a Bio-dot apparatus (Bio-Rad). The blot was fixed in 0.05% glutaraldehyde
in PBS for 20 min at RT, washed in PBS, blocked, and probed for HD5 with
an anti-HD5 serum.
Supplemental Data
The Supplemental Data include Supplemental Experimental Procedures and
three supplemental figures and can be found with this article online at http://
www.cellhostandmicrobe.com/cgi/content/full/3/1/11/DC1/.
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